Receptor News and Research

RSS

Metformin shows promise in treating AFib recurrence after ablation

People with atrial fibrillation (AFib) and obesity may have fewer episodes of AFib after ablation if they take the diabetes medication metformin in addition to standard care, according to a preliminary, late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Novel triple receptor agonist shows potent efficacy in lowering high triglycerides

In a small, short duration trial (12 weeks), a new medication called DR10624 reduced triglyceride levels in most patients with severe hypertriglyceridemia by more than 60%, according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

11 Nov 2025

Preclinical study reveals dampened neuronal activity in alcohol-exposed mice

A psychedelic found in mushrooms is emerging as a potential treatment for alcohol use disorders. This possibility is due to a compound the body converts the psychedelic into called psilocin, but psilocin's mechanisms remain unclear.

11 Nov 2025

St. Jude study maps treatment strategy for rare infant gliomas

Clinician-scientists at St. Jude Children's Research Hospital and collaborators have conducted the largest study of infant-type hemispheric glioma (IHG) ever reported, uncovering key factors that could be used to guide treatment strategies for this rare pediatric brain tumor.

11 Nov 2025

Age impacts systemic therapy outcomes in metastatic prostate cancer

Many things are evaluated when doctors are putting a treatment plan together for prostate cancer patients. A new study says one more factor should be considered – chronological age.

10 Nov 2025

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.

10 Nov 2025

Single daily polypill improves heart function and quality of life in heart failure patients

Adults with heart failure with reduced ejection fraction (HFrEF) who took a "polypill" combining medications prescribed for the treatment of heart failure, had improved heart function and symptoms, better quality of life, fewer hospitalizations and greater medication adherence than those taking the medications individually, according to a late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.

10 Nov 2025

Blood protein pattern linked to increased risk of hereditary atherosclerosis

A specific pattern of proteins in the blood may reflect an increased risk of hereditary atherosclerosis. This is shown in a new study from Karolinska Institutet, examining close relatives of people who had suffered a heart attack at a young age.

10 Nov 2025

Diabetes drugs semaglutide and tirzepatide show real-world heart benefits

In a large real-world analysis across three U.S. healthcare databases, semaglutide and tirzepatide showed cardiovascular benefits consistent with randomized trials. Semaglutide lowered heart attack and stroke risk versus sitagliptin, while tirzepatide performed comparably to dulaglutide and semaglutide over one year.

10 Nov 2025

Daily oral medication matches injectable therapies in reducing bad cholesterol

Among people with a previous heart attack or stroke, or who are at high risk for one, a daily oral medication may offer an effective alternative to injections of PCSK9 inhibitors to lower low-density lipoprotein (LDL or "bad" cholesterol), according to a preliminary late-breaking science presentation today at the American Heart Association's Scientific Sessions 2025.

10 Nov 2025

One cup of coffee a day could keep atrial fibrillation from coming back

A multicenter randomized clinical trial found that moderate caffeinated coffee intake after cardioversion significantly lowered the recurrence of atrial fibrillation or flutter compared with abstinence. The findings challenge long-standing advice to avoid coffee in cardiac arrhythmia patients and support its safety at typical consumption levels.

10 Nov 2025

Study provides insights into the obesity–breast cancer link

Obesity and cancer are two major health challenges of our time, yet the link between them remains only partially understood.

10 Nov 2025

Study identifies thyroid hormone pathway as key player in prostate cancer development

A hormone produced in the thyroid gland can play a key role in the development of prostate cancer.

10 Nov 2025

Weight loss drugs used by patients with high triglycerides do not increase pancreatitis risk

In a major new study, researchers from Intermountain Health in Salt Lake City have found that weight loss drugs used by patients who have high triglycerides do not increase their risk of pancreatitis or adverse cardiac events.

10 Nov 2025

Complete revascularization reduces the risk of death from cardiovascular causes

Opening all blocked arteries with stents in patients with a heart attack, known as complete revascularization, reduces the risk of death from cardiovascular causes, death from any cause and future heart attacks compared with opening only culprit artery causing the heart attack according to a new, large international study led by researchers at the Population Health Research Institute (PHRI), a joint organization of McMaster University and Hamilton Health Sciences.

10 Nov 2025

Genetic and cellular mechanisms underlying steatotic liver disease

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology.

10 Nov 2025

Drinking orange juice daily may fine-tune genes tied to cardiovascular wellness

Regular orange juice consumption reprograms immune-cell gene activity linked to blood pressure, lipid metabolism, and inflammation in healthy adults. The molecular effects differ by body weight, suggesting BMI-tailored benefits from this everyday beverage.

9 Nov 2025

New NIH grants fuel research in oral cancer treatment and pain relief

Researchers at the School of Dentistry at UT Health San Antonio, the academic health center of The University of Texas at San Antonio, have been awarded three multi-year grants totaling $6 million from the National Institutes of Health to address treatment and pain management for oral cancer.

7 Nov 2025

New radioimmunotherapy approach shows potential to cure HER2-positive breast cancer

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine.

7 Nov 2025